Back Login to subscribe 🔔 Set Alert

SGMT Sagimet Biosciences Inc. Series A Common Stock

Sector: Healthcare

Industry: Biotechnology

15 min delay

Today's News Sentiment

Loading...

Upcoming Earnings

Loading...

SGMT Fundamental Data

Loading...

Similar Companies

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

SGMT Insider Transactions

Loading insider data…

SGMT News

Date	Headline	Sentiment
	Sagimet Biosciences To Present 52-Week Results From Its Phase 3 ASC40-304 Open-Label Extension Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris At The 2026 Fall Clinical Dermatology Conference, October 8-11	70.31%
	HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target	91.16%
	Guggenheim Maintains Buy on Sagimet Biosciences, Raises Price Target to $26	84.53%
	Oppenheimer Maintains Outperform on Sagimet Biosciences, Raises Price Target to $38	90.04%
	Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $27	96.09%
	Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise	86.43%
	Sagimet Biosciences shares are trading higher after the company announced 52-week results from the Phase 3 ASC40-304 OLE trial of denifanstat for acne. The company suspended its at-the-market sale through Leerink Partners and announced the pricing of its $115 million offering of 8,750,010 shares at $10.00 per share.	91.7%
	Sagimet Biosciences Prices $115M Offer Of Shares And Warrants At $10.00/Unit	92.72%
	Sagimet Biosciences Suspends And Terminates August 14 Prospectus Supplement Regarding ATM Sales Agreement With Leerink	58.07%
	Sagimet Biosciences Announces 52-week Results From The Phase 3 ASC40-304 OLE Trial Of Denifanstat In Patients With Moderate To Severe Acne Vulgaris; Denifanstat Showed Progressive And Sustained Improvements Across All Efficacy Endpoints In The OLE, Including Investigator's Global Assessment Success With A Response Rate Of 57%, 72% Reduction In Total Lesions, And 77% Reduction In Inflammatory Lesions, And Was Generally Well-Tolerated, With No Adverse Event-Related Permanent Discontinuations	83.65%

1
2
›